Unicycive Therapeutics Inc (UNCY)

$BW $UNCY has a wonder drug that lower pill number by half, pill volume by 7 folds in treating kidney deseases. It is doing manufacturing certification required by fda. Once its done. Massive. tutes are loaded with this. $AMD $SNDK

$UNCY 👀

With everything going on around $UNCY lately, this is the info you don’t want to miss. #UNCY #Unicycive https://11th.com/cases/unicycive-investor-suit?utm_source=stocktwits&utm_medium=referral&utm_campaign=case&utm_content=11142025

$UNCY niceee ***FOLLOW ME for more winning calls!***

$UNCY 20% increase in shares shorted from prior month. i'm inclined to think there will be a moderate covering of those very soon.

$UNCY I’m happy to see that, for once, staying in ended up being a good choice. With a timeline in place and funding in order, it seems better days are ahead.

Raymond James🏁 $MAZE Outperform/$48 $VRTX $UNCY $OTSKY Raymond James said: The Maze Compass platform leverages genetic insights to discover novel therapies for genetically validated targets. MAZE's lead wholly-owned assets target high unmet need chronic kidney disease (CKD) populations: MZE829, an oral APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease (AMKD), and MZE782, an oral SLC6A19 inhibitor entering Phase 2 in phenylketonuria (PKU) and CKD. Both assets have best-in-class potential in attractive commercial indications and encouraging early mechanistic de-risking, in our view. While shares have roughly doubled from the January 2025 IPO, we believe MAZE continues to offer a very compelling risk/ reward skew into key Phase 2 readouts for MZE829 and MZE782 beginning in 2026.

Noble Capital Markets Research Report: Unicycive Therapeutics ($UNCY) – FDA Filing Date for OLC Confirmed With 3Q25 Reporting 3Q25 Reported With OLC Update. Unicycive reported a 3Q25 loss of $6.0 million or $(0.33) per share, below our expectations of $(8.4) million. Importantly, the company confirmed previous plans to resubmit its NDA for OLC (oxylanthanum citrate) by the end of the year, implying a new PDUFA date during 1H26. Cash at the end of the quarter was $42.7 million. Read more: https://www.channelchek.com/news-channel/unicycive-therapeutics-uncy-fda-filing-date-for-olc-confirmed-with-3q25-reporting

$UNCY way undervalued

$UNCY Checkout the price targets of these FIVE STAR analysts !

Unicycive Therapeutics (Nasdaq: $UNCY ) announced Q3 2025 results and remains on track to resubmit its NDA for oxylanthanum carbonate (OLC) by year-end. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. The company reported solid progress on multiple fronts, including resolution of FDA manufacturing concerns, presentation of compelling pill burden reduction data at ASN Kidney Week 2025, and a strengthened balance sheet with $42.7 million in cash providing runway into 2027. The company’s lead drug candidate OLC demonstrated a 7-fold reduction in pill volume and 2-fold reduction in pill count compared to current phosphate binders, addressing a major patient compliance challenge in dialysis treatment. Among other highlights from the Q3 report were: • Successful EU regulatory inspection of third-party manufacturing vendor with no deficiencies identified, supporting path to NDA resubmission • FDA Type A meeting confirmed single CRL deficiency related to manufacturing vendor, with no issues regarding preclinical, clinical, or safety data • Potential PDUFA date in first half of 2026 following anticipated NDA resubmission by year-end Dr. Shalabh Gupta, MD Gupta, CEO of Unicycive, commented, “With a continued commitment to advancing OLC, we are poised to resubmit the NDA for OLC by the end of the year, following positive discussions with the FDA and our third-party manufacturing vendor. Our focus has always been on enhancing the lives of people with hyperphosphatemia, as evidenced by the promising new data presented at ASN Kidney Week 2025 that showcase OLC’s differentiated clinical profile and reduced pill burden compared to currently available phosphate binders. See today’s press release at https://ir.unicycive.com/news/detail/114/unicycive-therapeutics-announces-third-quarter-2025. Unicycive Therapeutics is a clinical-stage biotechnology company developing innovative therapies for kidney diseases. The company’s lead investigational treatment, oxylanthanum carbonate, is a novel phosphate-binding agent for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Its second program, UNI-494, targets conditions related to acute kidney injury and has received FDA orphan drug designation for preventing delayed graft function in kidney transplant patients. Led by CEO Dr. Shalabh Gupta, MD Gupta and a seasoned executive team including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is committed to addressing unmet needs in kidney disease treatment. Learn more at Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/). Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted UNCY stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$UNCY This should be approved next year…delay is inevitable but showing some life today!

$UNCY niceee ****FOLLOW ME for more winning calls!****

$UNCY didn't take the 10% pop 2 weeks ago, but I did now. Lost $100, whatever. I'll come back of it drops back to mid 4s or closer to the new PFUDA

$UNCY Buyout waiting

$UNCY A last chance to buy below $5 ???

$UNCY 10-Q filed. https://www.sec.gov/ix?doc=/Archives/edgar/data/1766140/000121390025108600/ea0264250-10q_unicycive.htm#fact-identifier-1119 • As of November 12 there are 21,491,396 outstanding shares. • Increase in shares and cash from Q2 is primarily due to the ATM. In Q3 they issued 6,037,120 shares under the ATM, raising net proceeds of $26.4M. After Q3, they have so far issued an additional 641,033 shares under the ATM for net proceeds of $3M. • On Aug 26, 3,199.21 shares of Series A-2 Prime Preferred Stock were converted into 652,900 shares of common stock.

$UNCY Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update https://ir.unicycive.com/news/detail/114/unicycive-therapeutics-announces-third-quarter-2025 - On track to resubmit NDA by year end - $42.7m at end of Q3, runway into 2027

$UNCY Dilution. Dilution. Dilution.

With everything going on around $UNCY lately — this is the info you don’t want to miss. #UNCY #Unicycive https://11th.com/cases/unicycive-investor-suit?utm_source=stocktwits&utm_medium=referral&utm_campaign=case&utm_content=11072025

$UNCY Updated investor slide deck, I assume this is what they will use with today's presentation. https://d1io3yog0oux5.cloudfront.net/_8197568521755b8ac7c5352166835fca/unicycive/db/1912/17804/pdf/UNCY+Corporate+Deck++-++November+2025.pdf • Reiterates guidance for NDA resubmission by EOY 2025, with potential approval in 1H 2026 • Last slide states $42M in cash as of Sep 30, with runway into 2027. • 17.7m shares as of Aug 14. Confirms that they used the ATM through Aug 14 to raise $16.3M. "Share counts as of August 14, 2025. Common shares outstanding includes approximately 3.5 million shares sold between July 1, 2025 and August 14, 2025 pursuant to a sales agreement with Guggenheim Securities, LLC, resulting in net proceeds to the Company of approximately $16.3 million." If they used the ATM after Aug 14, it should be confirmed in the 10-Q for Q3, which will be filed this week (filing deadline Nov 14). Since they reported $22.3M as of Jun 30 in the Aug ER, I assume they have used the ATM since Aug 14. $22.3 + $16.3 = $38.6, which is short of the $42M on hand as of Sept 30.

$UNCY Presentation this afternoon at the Guggenheim Healthcare Innovation Conference. https://event.summitcast.com/view/6h3HS7z68WnTQE5PS7Vq8J/guest_book?session_id=CM8ox9ws3UkX4PHvvV4yfX 3:30pm ET